Prof. Apostolos Zaravinos – Cancer Genetics – Excellence in Research

Published on by Oncology

Prof. Apostolos Zaravinos - Cancer Genetics - Excellence in Research

European University Cyprus - Cyprus

Author Profile

Google Scholar

Orcid

Scopus

EARLY ACADEMIC PURSUITS

Dr. Apostolos Zaravinos began his academic journey with a B.Sc. in Molecular Biology from the Department of Biology at the University of Crete in 2004. He further pursued his passion for medicine by obtaining his Ph.D. in Medicine from the Medical School of the same university in 2008. These foundational academic pursuits laid the groundwork for his subsequent research and professional endeavors in the field of cancer genetics and molecular biology.

PROFESSIONAL ENDEAVORS

After completing his Ph.D., Dr. Zaravinos embarked on a series of professional roles that enriched his expertise and contributed to the scientific community. He worked as a Research Scientist at the Harris Birthright Research Center for Fetal Medicine at King’s College Hospital from 2009 to 2010. Subsequently, he performed postdoctoral research in Cancer Genetics at the Molecular Medicine Research Center of the University of Cyprus from 2011 to 2013. He further honed his skills in Immunogenetics and Cancer Genetics during his postdoctoral training at the Department of Laboratory Medicine of the Karolinska Institute from 2013 to 2015.In 2015, Dr. Zaravinos was appointed as an Assistant Professor of Cancer Genetics at the European University Cyprus. He was promoted to the rank of Associate Professor in 2019. He also served as an Associate Professor of Genetics at the Department of Basic Medical Science, College of Medicine (CMED) at Qatar University from 2020 to 2021. These academic positions allowed him to mentor students, lead research projects, and contribute to the advancement of cancer genetics and immunogenetics.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Dr. Zaravinos' research contributions are significant and multifaceted. His primary research aim is to achieve an advanced understanding of carcinogenesis by investigating interactions between genes. He is particularly interested in Cancer Immunogenetics and aims to elucidate how the tumor microenvironment relates to different aspects of tumor biology. His research has focused on examining the immune landscape of inflamed tumors, including colorectal cancer and skin melanoma, using next-generation sequencing approaches.

IMPACT AND INFLUENCE

Dr. Zaravinos has made a substantial impact on the field of cancer genetics and immunogenetics. He has authored over 125 original research articles and 7 book chapters, demonstrating his prolific research output. His work has been cited over 3,600 times, with an h-index of 35, as documented on Scopus. His research findings have contributed to the scientific community's understanding of carcinogenesis, tumor immunology, and the tumor microenvironment.

ACADEMIC CITES

Dr. Zaravinos' research has garnered significant attention and recognition in the scientific community, as evidenced by his high citation count and h-index. His publications have been cited over 3,600 times, highlighting the impact and relevance of his research in the field of cancer genetics and immunogenetics.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Zaravinos' legacy in the field of cancer genetics and immunogenetics is characterized by his groundbreaking research, mentorship, and contributions to scientific literature. His work has paved the way for future research endeavors aimed at understanding carcinogenesis, tumor immunology, and the tumor microenvironment. As a dedicated researcher and educator, Dr. Zaravinos continues to inspire and influence the next generation of scientists, leaving a lasting impact on the field of cancer genetics and molecular biology. His future contributions are eagerly anticipated as he continues to explore new avenues in cancer research and mentor emerging scientists in the field.

NOTABLE PUBLICATIONS

Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1. 2024

Peptide absent sequences emerging in human cancers. 2024

Immune Cytolytic Activity and Strategies for Therapeutic Treatment. 2024

Strand asymmetries across genomic processes. 2023

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies. 2023 (3)

 

Dr. Michele Moreau – Oncology Therapeutics and Novel Approaches –  Best Researcher Award

Published on by Oncology

Dr. Michele Moreau - Oncology Therapeutics and Novel Approaches -  Best Researcher Award

Johns Hopkins University - United States

Author Profile

Orcid

EARLY ACADEMIC PURSUITS

Michele Moreau's academic journey began with a Bachelor of Science (B.S.) in Physics from the University of Kentucky in May 2009. Following this foundational degree, Michele pursued a Master of Science (M.S.) in Applied Physics from the Physics Department at the University of Massachusetts Boston, graduating in May 2012. Building upon this, Michele achieved another M.S. in Medical Physics from the Radiological Sciences Department at the University of Massachusetts Lowell in May 2022. These early academic pursuits set the stage for Michele's specialization in the field of biomedical engineering and biotechnology.

PROFESSIONAL ENDEAVORS

During Michele Moreau's academic journey, she served as a Teaching and Research Assistant at the University of Massachusetts Lowell from 2014 to 2023. Her role involved teaching an Introductory Physics Lab course and grading lab reports and quizzes. Furthermore, Michele completed a 6-month internship focused on developing a platform for catalyzing collaborative global Cancer Care Education and Research (CaRE). This initiative aimed to enhance Access to Medical Physics Education and Research Excellence (AMPERE), showcasing her commitment to global health initiatives.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY THERAPEUTICS AND NOVEL APPROACHES

Michele Moreau's primary research focus revolves around biomedical research in cancer therapy. As a Graduate Research Trainee from 2015 to 2023 at prestigious institutions such as Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Johns Hopkins School of Medicine, Michele specialized in engineering solid and liquid formulations of smart radiotherapy biomaterials. Her expertise encompasses a wide range of techniques and methodologies, including:Engineering Smart Radiotherapy Biomaterials,Monolayer and 3D Cell Culture etc.,

IMPACT AND INFLUENCE

Michele Moreau's research contributions have the potential to revolutionize cancer therapy by improving the effectiveness of in-situ treatment of tumor masses. Her work on smart radiotherapy biomaterials and associated techniques could significantly enhance the precision and efficiency of cancer treatments, benefiting countless patients worldwide.

ACADEMIC CITES

Michele's research findings and contributions to the field of biomedical engineering and biotechnology have likely been cited in various academic publications, journals, and conferences. Her collaborations with esteemed institutions and her focus on cutting-edge research topics make her a notable figure in the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As Michele Moreau is expected to be conferred with a Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts Lowell in August 2023, her legacy in the field is already taking shape. Her multidisciplinary approach to cancer therapy, combining physics, engineering, and biology, paves the way for future advancements in the field. Michele's dedication to improving cancer treatments and her commitment to global health initiatives highlight her potential to leave a lasting impact on biomedical research and patient care.

NOTABLE PUBLICATIONS

Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment. 2024

Pre-Clinical Investigations of the Pharmacodynamics of Immunogenic Smart Radiotherapy Biomaterials (iSRB). 2023

Smart Radiotherapy Biomaterials for Image-Guided In Situ Cancer Vaccination. 2023

Polydopamine Nanomaterials for Overcoming Current Challenges in Cancer Treatment. 2023

Phytoradiotherapy to enhance cancer treatment outcomes with cannabidiol, bitter melon juice, and plant hemoglobin. 2023

 

 

Assist Prof Dr. Iftekhar Hossain Chowdhury – Cancer Science – Best Review Article Award

Published on by Oncology

Assist Prof Dr. Iftekhar Hossain Chowdhury - Cancer Science - Best Review Article Award

Mugda Medical College – Bangladesh

AUTHOR PROFILE

Google Scholar

EARLY ACADEMIC PURSUITS

Dr. Iftekhar Hossain Chowdhury embarked on his academic journey in the field of medicine by completing his undergraduate MBBS degree in 2009 from Dinajpur Medical College Hospital, Dinajpur under Rajshahi University, Bangladesh.

PROFESSIONAL ENDEAVORS

Following his undergraduate studies, Dr. Iftekhar pursued further specialization in Pharmacology. In 2023, he successfully completed his post-graduation MD (Pharmacology) from Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Currently, he serves as an Assistant Professor in the Department of Pharmacology at Mugda Medical College, Dhaka, Bangladesh.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Iftekhar has a special interest in drug repurposing and its toxicological implications in cancer patients. His research focuses on exploring the potential of existing drugs for new therapeutic purposes and understanding their toxicological effects, particularly in the context of cancer treatment.

IMPACT AND INFLUENCE

As a dedicated academic and researcher, Dr. Iftekhar's work has the potential to contribute significantly to the field of pharmacology and cancer therapeutics. His research findings could lead to the development of innovative treatment strategies and contribute to improving the quality of life for cancer patients.

ACADEMIC CITES

Dr. Iftekhar is a member of esteemed professional organizations, including the Bangladesh Society of Pharmacology and the International Union of Basic & Clinical Pharmacology (IUPHAR). His active participation in these organizations signifies his commitment to advancing the field of pharmacology through collaboration, knowledge sharing, and networking.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Iftekhar's dedication to academic pursuits and research in pharmacology positions him as a rising figure in the field. His contributions have the potential to shape future research directions, influence clinical practice, and contribute to the global fight against cancer.

NOTABLE PUBLICATION

Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-Cachexia in Advanced Cancer Patients: A Randomized, Double-Blind Trial. 2024

IUPHAR ECR review: Cancer-Related Anorexia-Cachexia in Cancer Patients: Pathophysiology and Treatment. 2024

Validation and Translation of Bengali Version of Functional Assessment of Anorexia Cachexia Therapy (Anorexia/Cachexia Subscale) for Measuring Cancer Related Anorexia Cachexia (CRAC) in Advanced Cancer Patients. 2023

Dr. Subhashree Choudhury – Oncology and Precision Medicine – Best Researcher Award

Published on by Oncology

Dr. Subhashree Choudhury - Oncology and Precision Medicine - Best Researcher Award

Faculty of Engineering and Technology (ITER), Siksha O Anusandhan (Deemed to be University) - India

Author Profile

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Dr. Subhashree Choudhury began her academic journey with a Bachelor's degree in Electrical Engineering from the Gandhi Institute of Technological Advancement (GITA), affiliated with Biju Patnaik University of Technology (BPUT). She further pursued her Master's degree in Power Electronics and Drives and later obtained a Ph.D. in Electrical Engineering, both from the Institute of Technical Education & Research, Siksha ‘O’ Anusandhan (Deemed to be University). Notably, she was awarded the Gold Medal for her outstanding performance during her M. Tech studies.

PROFESSIONAL ENDEAVORS

Dr. Choudhury's professional career spans over a decade, starting as a Lecturer at Sanjay Memorial Institute of Technology, affiliated with BPUT, from 2009 to 2010. She then progressed to the position of Assistant Professor at the Institute of Technical Education & Research/Siksha ‘O’ Anusandhan (Deemed to be University) from 2012 to 2018. Currently, she serves as an Associate Professor in the Department of Electrical and Electronics Engineering at the same institution.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Dr. Choudhury has made significant contributions to the field of Electrical Engineering, particularly in the Energy domain. Her research focuses on innovative approaches to energy systems, aiming to enhance efficiency and sustainability. Her work has been recognized by Elsevier B.V. and Stanford University, ranking her among the top 2% of scientists in the Energy domain.

IMPACT AND INFLUENCE

With her expertise and dedication, Dr. Choudhury has had a substantial impact on the academic and professional communities. Her research and contributions have paved the way for advancements in energy systems and have inspired budding engineers and researchers in the field.

ACADEMIC CITATIONS

As a testament to her scholarly work, Dr. Choudhury's research has garnered numerous citations, reflecting the significance and influence of her contributions to the field of Electrical Engineering and Energy systems.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Subhashree Choudhury's legacy in the field of Electrical Engineering and Energy systems is characterized by her groundbreaking research, academic achievements, and impactful contributions. As an Associate Professor and a leading figure in her field, she continues to inspire and mentor the next generation of engineers and researchers. Her future contributions are eagerly anticipated, as she remains committed to advancing knowledge and fostering innovation in the realm of energy systems.

NOTABLE PUBLICATIONS

The Optimization of PEM Fuel-Cell Operating Parameters with the Design of a Multiport High-Gain DC–DC Converter for Hybrid Electric Vehicle Application. 2024

Intelligent Approach for Control Techniques Based on Complex Converter Structures. 2023

Data-Driven Bearing Fault Diagnosis for Induction Motor. 2023

Dynamic Voltage Restorer to Mitigate Voltage Sag/Swell using Black Widow Optimization Technique with FOPID Controller. 2023

Power Quality Improvement Using TID based DVR Controller. 2023

Mrs. Feryal Dabbagh-Gorjani – Tumor Immunology – Best Researcher Award

Published on by Oncology

Mrs. Feryal Dabbagh-Gorjani - Tumor Immunology - Best Researcher Award

Foroogh Salamat - Iran

Author Profile

Orcid

EARLY ACADEMIC PURSUITS

Feryal Dabbagh Gorjani embarked on her academic journey with a strong foundation in the medical sciences. She pursued a B.Sc in Clinical Laboratory from 2008 to 2010 at the Preclinical School of Iran University of Medical Science, Tehran, Iran. Prior to that, she obtained an associated degree in Clinical Laboratory from the Preclinical School of Islamic Azad University, Tehran Medical Sciences Branch, from 2005 to 2007. Her educational journey culminated in an M.Sc in Medical Immunology from 2011 to 2014 at the Medical School of Shiraz University of Medical Science, Shiraz, Iran.

PROFESSIONAL ENDEAVORS

From December 2023 onwards, Feryal Dabbagh Gorjani has been engaged as a medical advisor at Forough Salamat Mehregan, the official representative of the American company Fairhaven Health. Her role in this capacity involves providing expertise and guidance in medical matters, presumably within the realm of immunology and clinical laboratory science.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Throughout her academic and professional journey, Feryal Dabbagh Gorjani has likely contributed to the field of medical immunology and clinical laboratory science. And her Specific research focuses on immunological diagnostics, disease pathogenesis, and therapeutic interventions.

IMPACT AND INFLUENCE

Her work as a medical advisor suggests that she plays a crucial role in shaping decisions related to health and wellness. Her expertise in medical immunology and clinical laboratory science likely contributes to advancements in diagnostic accuracy, treatment efficacy, and patient care.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

Feryal Dabbagh Gorjani's legacy and future contributions lie in her ongoing work as a medical advisor and her potential for further advancements in the fields of medical immunology and clinical laboratory science. As she continues to apply her expertise and knowledge in healthcare settings, her contributions are likely to impact patient outcomes, research advancements, and the broader medical community. Future endeavors may include continued research, publications, and collaborative efforts to address emerging challenges in immunological diagnostics and therapeutics.

Notable Publications

A Comprehensive Review on the Role of Interleukin-40 as a Biomarker for Diagnosing Inflammatory Diseases. 2024

COVID-19 and neurological complications. 2022

EcoImmunology: Evaluative Aspects and Future Perspectives. 2018

Investigating the Association of IL-17A and IL-17F with Susceptibility to Preeclampsia in Iranian Women. 2015

Differences in the expression of TLRs and inflammatory cytokines in preeclamptic compared with healthy pregnant women. 2014

 

 

 

 

Dr.Muhammad Umar Farooq – ovarian cancer – Best Researcher Award

Published on by Oncology

Dr.Muhammad Umar Farooq - ovarian cancer - Best Researcher Award

School of Chemisry SJTU - China

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Muhammad Umar Farooq embarked on his academic journey with a Bachelor of Science degree in Physics/Mathematics from the University of The Punjab, Lahore, Pakistan. Building upon this foundation, he pursued an MSc in Physics from the University of Agriculture, Faisalabad, Pakistan, followed by an MS/M.Phil. in Physics from the International Islamic University Islamabad, Pakistan. These early academic pursuits provided him with a strong background in the fundamentals of physics, laying the groundwork for his future research endeavors.

PROFESSIONAL ENDEAVORS

With a solid academic background, Farooq ventured into the realm of research and academia. He pursued a Ph.D. in Electronic Science and Technology from the University of Electronic Science and Technology of China, where he delved into interdisciplinary research at the forefront of materials science and engineering. Subsequently, he took on the role of a Postdoctoral Researcher at Shanghai Jiao Tong University, China, further honing his expertise in materials processing, nanomaterials, nanocomposites, polymers, surface coating, and surface modifications.

CONTRIBUTIONS AND RESEARCH FOCUS ON OVARIAN CANCER

Farooq's contributions to the field are substantial, spanning a wide range of interdisciplinary research areas. His research focuses on materials processing, particularly in the development of advanced nanomaterials and nanocomposites. He has made significant strides in understanding the properties of polymers and exploring novel techniques for surface coating and modifications. His work not only advances fundamental understanding but also holds promise for practical applications in various industries.

IMPACT AND INFLUENCE

Farooq's research has garnered attention within the scientific community for its innovation and potential impact. His findings have been published in reputable journals, contributing to the body of knowledge in materials science and engineering. Through collaborations and knowledge exchange, he has influenced fellow researchers and students, fostering a culture of interdisciplinary exploration and innovation.

ACADEMIC CITATIONS

Farooq's publications have received citations from peers and researchers worldwide, underscoring the significance of his contributions to the field. His work serves as a point of reference for those engaged in materials research and related disciplines, highlighting the relevance and impact of his findings.

LEGACY AND FUTURE CONTRIBUTIONS

Farooq's legacy lies in his dedication to pushing the boundaries of materials science and engineering through interdisciplinary research. His work has laid a foundation for future advancements in areas such as materials processing, nanotechnology, and surface engineering. As he continues his academic journey, Farooq is poised to make further contributions that will shape the future of materials science, leaving a lasting impact on the field and beyond.

NOTABLE PUBLICATIONS

Single-atom catalysts for electrocatalytic applications: Synthetic strategies, in-situ characterization, and future challenges. 2024

Kinetics insights into the active sites of Au catalysts for the oxidative esterification of methacrolein to methyl methacrylate. 2023

Testing of magnetic and dielectric traits of microwave plasma treated NiCuZn spinel ferrites for efficient energy storage and high-frequency applications. 2023 (5)

Synergistic electronic and geometric effects of Au/<scp>CeO<sub>2</sub></scp> catalyst for oxidative esterification of methacrolein. 2023

Surface engineered AuNPs for paclitaxel-loaded bleomycin delivery as a supplementation therapy. 2022

Prof Dr.Ronny Priefer – Cancer Biomarkers – Best Researcher Award

Published on by Oncology

Prof Dr.Ronny Priefer - Cancer Biomarkers - Best Researcher Award

MCPHS University - United States

AUTHOR PROFILE

Scopus 

Orcid

EARLY ACADEMIC PURSUITS

Ronny Prieger's academic journey began with a Bachelor of Science degree in Chemistry from the University of Northern British Columbia. He then pursued his passion for organic chemistry, earning a Ph.D. from McGill University in Montreal, Quebec. His early academic pursuits laid a solid foundation for his future endeavors in the field of medicinal chemistry.

PROFESSIONAL ENDEAVORS

After completing his Ph.D., Ronny Prieger joined Neurochem Inc. in Saint-Laurent, Quebec, Canada, as a Post-Doctoral Fellow. This position provided him with valuable industry experience and exposure to neurochemistry research.Subsequently, Prieger transitioned into academia, where he served as an Associate Dean of Graduate Studies at the School of Pharmacy, Massachusetts College of Pharmacy and Health Science University (MCPHS) in Boston. He also held the position of Professor of Medicinal Chemistry in the Department of Pharmaceutical Sciences at MCPHS, further solidifying his role in academia.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER BIOMARKERS

Throughout his career, Ronny Prieger has made significant contributions to the field of medicinal chemistry. His research focus spans various areas, including neurochemistry, cancer biomarkers and organic chemistry. Prieger's work has contributed to advancing our understanding of drug development and neurodegenerative diseases.

IMPACT AND INFLUENCE

Prieger's contributions have had a notable impact on both academia and industry. His research findings have been instrumental in shaping the direction of medicinal chemistry research, particularly in the development of novel therapeutics for neurological disorders.

ACADEMIC CITATIONS

Ronny Prieger's research has garnered attention within the academic community, as evidenced by the numerous citations his work has received in scholarly publications. His contributions to the field have been recognized and cited by peers and colleagues, further solidifying his reputation as a respected researcher in medicinal chemistry.

LEGACY AND FUTURE CONTRIBUTIONS

As an established figure in the field of medicinal chemistry, Ronny Prieger's legacy extends beyond his current endeavors. His dedication to research and education has inspired future generations of scientists and pharmaceutical professionals. Moving forward, Prieger continues to make significant contributions to the field, with a focus on advancing drug discovery and improving treatments for neurological disorders.

NOTABLE PUBLICATIONS

Layer-by-layer assembly: A versatile approach for tailored biomedical films and drug delivery. 2024

A comparison of continuous glucose monitors (CGMs) in diabetes management: A systematic literature review. 2023

Comparison of small molecules VEGFR inhibitors in the treatment of renal cell carcinoma. 2023

Challenges Related to Extractables/Leachables During Bioprocessing. 2023

Detection technologies of volatile organic compounds in the breath for cancer diagnoses. 2023 (4)

Assoc Prof Dr.Tiruveedula Gopi Krishna – Cancer Science – Best Researcher Award

Published on by Oncology

Assoc Prof Dr.Tiruveedula Gopi Krishna - Cancer Science - Best Researcher Award

Adama Science and Technology University - Ethiopia

AUTHOR PROFILE

Google Scholar

Orcid

EARLY ACADEMIC PURSUITS

Dr. Tiruveedula Gopikrishna began his academic journey in the field of Computer Science and Engineering. His early academic pursuits laid the foundation for his future contributions in the realm of technology and information sciences.

PROFESSIONAL ENDEAVORS

Having demonstrated a keen interest in the field, Dr. Gopikrishna embarked on a professional journey that led him to the position of Assistant Professor and subsequently Associate Professor at Adama Science & Technology University in Ethiopia. His commitment to academia reflects in his multifaceted roles and responsibilities.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Gopikrishna's expertise encompasses a diverse range of subjects, including Data Science, Big Data, Artificial Intelligence, Machine Learning, Deep Learning, Distributed Systems, Data Warehousing, Data Mining, Cloud Computing, C, Python, C++, Java, Web Technologies, and SQL. His research focus extends to critical areas such as Big Data Analytics and Visualization, Software Testing Methodologies, Middleware, and the intersection of big data with cloud computing.

IMPACT AND INFLUENCE

Dr. Gopikrishna's impact is evident in the significant contributions he has made to the academic and research community. His influence extends beyond the classroom, shaping the minds of aspiring technologists and researchers under his guidance.

ACADEMIC CITES

The academic prowess of Dr. Gopikrishna is underscored by his extensive experience in teaching undergraduate and postgraduate subjects. He has been instrumental in guiding 56 undergraduate projects and supervising 4 master's degree theses, showcasing his commitment to fostering academic excellence.

LEGACY AND FUTURE CONTRIBUTIONS

As an Associate Professor, Dr. Gopikrishna has already established a legacy in academia. His dedication to shaping the next generation of tech professionals and researchers is evident. Looking forward, his future contributions are poised to further enrich the fields of Computer Science and Information Technology, leaving an indelible mark on the academic landscape.

NOTABLE PUBLICATIONS

An Improved Switch Migration Method Based Efficient Load Balancing for Multiple Controllers in Software Defined Network. 2023

DDoS Attack Detection and Classification Using Hybrid Model for Multi-controller SDN. 2023 (3)

Classification of Brain Tumor Types on Magnetic Resonance Images Using Hybrid Deep Learning Approach with Radial Basis Function Neural Network. 2022

Breast Cancer Classification from Mammogram Images Using Extreme Learning Machine-Based DenseNet121 Model. 2022 (5)

Designing and Developing Bilingual Chatbot for AssistingEthio-Telecom Customers on Customer Services. 2022

Dr. Hiu Yee Kwan – Obesity and Cancer – Women Researcher Award

Published on by Oncology

Dr. Hiu Yee Kwan - Obesity and Cancer - Women Researcher Award

Hong Kong Baptist University - Hong Kong

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Kwan Hiu Yee's academic journey began with a strong foundation in the sciences. She earned a B.Sc. with 2nd Honors Upper Class in Biology and Biotechnology from the Faculty of Science at The University of Hong Kong (1992-1995).

PROFESSIONAL ENDEAVORS

Continuing her academic pursuits, Kwan Hiu Yee completed her Ph.D. at the Department of Physiology, Faculty of Medicine, The Chinese University of Hong Kong (2001-2006). She further honed her expertise by obtaining a Certificate in Epidemiology & Control of Infectious Diseases from the School of Public Health at The Chinese University of Hong Kong in 2005.

CONTRIBUTIONS AND RESEARCH FOCUS ON OBESITY AND CANCER

Kwan Hiu Yee's research focus has been on the intersection of physiology, public health, and Chinese medicine. Her contributions extend to the exploration of vascular ion channel targets in cardiovascular diseases, as evidenced by winning the Second Prize of China Medical Science and Technology Award in 2020.

IMPACT AND INFLUENCE

As an Associate Professor and Associate Director in the Teaching and Research Division at the Centre for Cancer & Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Kwan Hiu Yee plays a pivotal role in shaping the academic landscape.

ACADEMIC CITES

Her impactful work is reflected in numerous academic accolades, including the CUHK Young Scholars Dissertation Awards nomination in 2007 and the HKBU School Performance Award in Teaching in 2022.

LEGACY AND FUTURE CONTRIBUTIONS

Kwan Hiu Yee's legacy is marked by her active involvement in professional memberships, such as the International Society for Extracellular Vesicles and the Hong Kong Association for the Study of Obesity and Cancer. With a diverse skill set, including a Master of Arts in Translation & Linguistics, she continues to contribute to academia.

NOTABLE PUBLICATIONS

Elevated extracellular matrix protein 1 in circulating extracellular vesicles supports breast cancer progression under obesity conditions. 2024

Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axis. 2024

Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay. 2023 (3)

Control of SARS-CoV-2 infection by MT1-MMP-mediated shedding of ACE2. 2022 (6)

Omics approach to reveal the effects of obesity on the protein profiles of the exosomes derived from different adipose depots. 2022

Dr. Takashi Takeshita – Cancer Genetics – Best Researcher Award

Published on by Oncology

Dr. Takashi Takeshita - Cancer Genetics - Best Researcher Award

Kumamoto City Hospital - Japan

Author Profile

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Takashi Takeshita initiated his academic journey by obtaining a Medical Doctorate (M.D.) from the National Defense Medical College, Saitama, Japan, in 2005. He furthered his education by earning a Ph.D. from St. Marianna University School of Medicine, Kanagawa, Japan, in 2012. These early academic pursuits established the foundation for his future contributions to cancer genetics.

PROFESSIONAL ENDEAVORS

Since 2022, Takashi Takeshita has been serving as the Chief of Breast and Endocrine Surgery at Kumamoto City Hospital, Japan. His professional journey is marked by significant achievements, including the receipt of several prestigious awards: the 2017 Research Award from the Japanese Breast Cancer Society, the 2017 Research Award from the Japanese Society of Medical Oncology, the 2018 Young Investigator’s Award from the Japan Surgical Society, and the 2018 Excellent Presentation Award from the Japanese Breast Cancer Society.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS 

Takashi Takeshita's 19-year research career spans various research institutes, showcasing a robust expertise in cancer genetics. His focus includes genetic analysis of clinical specimens, utilizing techniques such as digital PCR for tumor tissue and plasma DNA, immunohistochemical staining, automated assay robot operation, and more. His experience in large-scale cell culture and comprehensive knowledge of molecular biology, pharmacology, and analytical methods underscore his dedication to advancing cancer research.

IMPACT AND INFLUENCE

The awards received by Takashi Takeshita, coupled with his role as the Chief of Breast and Endocrine Surgery, affirm his impact and influence in the medical field. His leadership and contributions to cancer genetics, particularly in breast cancer research, position him as a prominent figure. His membership in esteemed academic societies, including the Japanese Breast Cancer Society, Japan Surgical Society, Japanese Cancer Association, Japanese Society of Medical Oncology, and the American Association for Cancer Research, further reflects his influence on a global scale.

ACADEMIC CITES

Takashi Takeshita's involvement in renowned academic societies and receipt of research awards suggest that his work likely receives recognition and citations within the scientific community. His expertise in genetic analysis and clinical research contributes to the advancement of cancer genetics literature.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

Takashi Takeshita's legacy is built upon a foundation of excellence in cancer genetics, marked by numerous awards and leadership roles. His dedication to advancing breast and endocrine surgery and his contributions to genetic analysis techniques set the stage for a lasting impact. Looking ahead, Takeshita is poised to continue making significant contributions to cancer genetics, shaping the future landscape of research in breast cancer and beyond. His membership in international societies signifies a commitment to global collaboration and further advancements in cancer research.

NOTABLE PUBLICATIONS

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing. 2024

Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment. 2023

Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer. 2023 (5)

Fulvestrant plus palbociclib in advanced or metastatic hormone. 2023 (2)

High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment. 2023